Efficacy and safety of once‐weekly semaglutide versus once‐daily sitagliptin as add‐on to metformin in patients with type 2 diabetes in SUSTAIN China : A 30‐week, double‐blind, phase 3a, randomized trial
Open accessAbstract
Aim: To evaluate the efficacy and safety of once‐weekly subcutaneous semaglutide, a glucagon‐like peptide‐1 (GLP‐1) analogue, versus once‐daily sitagliptin as add‐on to metformin in patients with type 2 diabetes (T2D) in a multiregional clinical trial. Materials and Methods: In the 30‐week, randomized, double‐blind, double‐dummy, active comparator SUSTAIN China trial, 868 adults with T2D inadequately controlled on metformin (HbA1c 7.0%‐10.5%) were randomized to receive once‐weekly semaglutide 0.5 mg (n = 288), semaglutide 1.0 mg (n = 290) or once‐daily sitagliptin 100 mg (n = 290). The primary and confirmatory secondary endpoints were change from baseline to week 30 in HbA 1c and body weight, respectively. Results: The trial enrolled ~70% (605/868) of the patients in China, and the remaining patients from four other countries, including the Republic of Korea. Both doses of semaglutide were superior to sitagliptin in reducing HbA 1c and body weight after 30 weeks of treatment. The odds of achieving target HbA 1c of less than 7.0% (53 mmol/mol), weight loss of 5% or higher, or 10% or higher, and the composite endpoint of HbA 1c less than 7.0% (53 mmol/mol) without severe or blood glucose‐confirmed symptomatic hypoglycaemia no weight gain, were all significantly higher with both semaglutide doses compared with sitagliptin. The safety profile for semaglutide was consistent with the known class effects of GLP‐1 receptor agonists (RAs). Consistent efficacy and safety findings were seen in the Chinese subpopulation. Conclusions: Once‐weekly semaglutide was superior to sitagliptin in improving glycaemic control and reducing body weight in patients with T2D inadequately controlled on metformin. The safety and tolerability profiles were consistent with those of semaglutide and other GLP‐1 RAs. Semaglutide is an effective once‐weekly treatment option for the Chinese population.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A randomized trial conducted in China for 30 weeks showed that semaglutide caused a significant reduction in the likelihood of major adverse cardiovascular events by 26% and decreased the occurrence of stroke by 39% in comparison to placebo.
“a randomized trial conducted in China for 30 weeks, with a double-blind and phase 3a design, showed that semaglutide caused a significant reduction in the likelihood of major adverse cardiovascular events by 26% and decreased the occurrence of stroke by 39% in comparison to placebo.”
From Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta‐analysis including the 2‐year <scp>STEP</scp> 5 trial (2024) · cites this paper as [40]
Split into 2 atoms — 0 confirmed, 1 partially supported, 1 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredIn the sitagliptin comparison group of 1518 patients, severe hypoglycemia occurred in 62 cases, approximately 4.08%.
“The sitagliptin group comprised 1518 patients, within which there were 62 reported cases of severe hypoglycemia, resulting in a proportion of approximately 4.08%.”
From Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review (2024) · cites this paper as [48]
The Results (Participant disposition and baseline characteristics) report 290 patients in the sitagliptin group, not 1,518. The Results (Safety and tolerability) explicitly state that no severe hypoglycaemia episodes were reported; Table 3 lists four sitagliptin patients (1.4%) with severe or blood-glucose-confirmed hypoglycaemia, a broader category than severe hypoglycaemia alone. (LLM, conf=0.95)
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredIn the sitagliptin comparison group, acute kidney injury occurred in 3 cases (0.20%).
“this group experienced a lower incidence of acute kidney injury (AKI) and pancreatitis, with only three cases (0.20%) and one case (0.07%), respectively.”
From Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review (2024) · cites this paper as [48]
The Results (Participant disposition and baseline characteristics) state that the sitagliptin group had 290 patients. Three cases among 290 patients would be about 1.03%, not 0.20%, so the claimed percentage is incompatible with this trial's group size. The passages found do not report an acute kidney injury count. (LLM, conf=0.78)
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredIn the sitagliptin comparison group, pancreatitis occurred in 1 case (0.07%).
“this group experienced a lower incidence of acute kidney injury (AKI) and pancreatitis, with only three cases (0.20%) and one case (0.07%), respectively.”
From Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review (2024) · cites this paper as [48]
The Results (Safety and tolerability, Table 3) report zero EAC-confirmed mild acute pancreatitis cases in the sitagliptin group. The single case occurred in the semaglutide 1.0 mg group, where it represented 0.3%, not 0.07%. (LLM, conf=0.95)
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredSemaglutide is effective for weight loss in the general population.
“Across these trials, semaglutide demonstrated significant body weight reductions from baseline to end of treatment versus all comparators.”
From Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series (2023) · cites this paper as [24]
The Introduction reports greater body-weight reductions with semaglutide than with placebo and a range of active comparators across the SUSTAIN trials. The Discussion reports greater weight reduction than with sitagliptin in this trial. These findings concern patients with type 2 diabetes, not the general population, so they do not support that broader population claim. (LLM, conf=0.88)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667 · see citing works
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419 · see citing works
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · see citing works
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 4× · see citing works
“Furthermore, semaglutide was also associated with a significant 26% reduction in the risk of major adverse cardiovascular events compared with placebo in a preapproval cardiovascular outcomes trial (CVOT).(30) Chinese regulatory guidelines require that the efficacy and safety of semaglutide is evaluated in a clinical…”
BackgroundResultInfluentialSelf-citationGupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,019 · see citing works
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518 · see citing works
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163 · see citing works
Prevalence and Ethnic Pattern of Diabetes and Prediabetes in China in 2013
Wang, L., Gao, P., Zhang, M., Huang, Z., Zhang, D., Deng, Q., Yichong, L., Zhao, Z., Qin, X., Jin, D., et al. (2017) · JAMA · doi:10.1001/jama.2017.7596 · Cited by 1,849 · see citing works
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · see citing works
(2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.334 · Cited by 1,162 · cited 1× · see citing works
“It is known that a weight loss of 5% or more is associated with improved glycaemic control in patients with T2D, and weight loss is therefore a cornerstone of T2D treatment.(7,13,14) The pathophysiology of T2D in East Asians involves reduced insulin secretory capacity and less insulin resistance compared with Caucasia…”
BackgroundDiscovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105 · cited 1× · see citing works
“These modifications prolong its half-life through enhanced binding to albumin and inhibition of degradation by DPP-4, facilitating once-weekly dosing.(18) The efficacy and safety of semaglutide have been established in more than 10 000”
BackgroundPratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790 · see citing works
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745 · see citing works
6. Glycemic Targets: <i>Standards of Medical Care in Diabetes—2020</i>
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s006 · Cited by 744 · see citing works
Standards of medical care for type 2 diabetes in China 2019
Jia, W., Weng, J., Zhu, D., Ji, L., Lu, J., Zhou, Z., Zou, D., Guo, L., Ji, Q., Chen, L., et al. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3158 · Cited by 703 · see citing works
Self-citationAhmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596 · see citing works
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S. E., DeFronzo, R. A., EINHORN, D. F., Fonseca, V. A., et al. (2018) · Endocrine Practice · doi:10.4158/cs-2017-0153 · Cited by 499 · see citing works
Ahrén, B., Masmiquel, L., Kumar, H., Sargin, M., Karsbøl, J. D., Jacobsen, S. H., & Chow, F. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30092-x · Cited by 495 · see citing works
Introduction: <i>Standards of Medical Care in Diabetes—2018</i>
(2018) · Diabetes Care · doi:10.2337/dc18-sint01 · Cited by 472 · see citing works
Aroda, V. R., Bain, S. C., Cariou, B., Piletič, M., Rose, L., Axelsen, M., Rowe, E., & DeVries, J. H. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30085-2 · Cited by 464 · see citing works
Nauck, M. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12591 · Cited by 429 · cited 1× · see citing works
“of BG-confirmed hypoglycaemia was low and similar among treatment groups, in line with the glucose-dependent mechanism of action of both GLP-1 RAs and DPP-4 inhibitors.(36) These results, combined with”
ResultCapehorn, M. S., Catarig, A.-M., Furberg, J. K., Janez, A., Price, H. C., Tadayon, S., Vergès, B., & Marre, M. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.101117 · Cited by 412 · see citing works
Zinman, B., Bhosekar, V., Busch, R., Holst, I., Ludvik, B., Thielke, D., Thrasher, J., Woo, V., & Philis-Tsimikas, A. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30066-x · Cited by 376 · see citing works
β Cell Dysfunction Versus Insulin Resistance in the Pathogenesis of Type 2 Diabetes in East Asians
Yabe, D., Seino, Y., Fukushima, M., & Seino, S. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0602-9 · Cited by 328 · see citing works
Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy
Vilsbøll, T., Bain, S. C., Leiter, L. A., Lingvay, I., Matthews, D., Simó, R., Helmark, I. C., Wijayasinghe, N., & Larsen, M. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13172 · Cited by 318 · cited 1× · see citing works
“The use of semaglutide has previously been associated with a higher rate of retinopathy-related complications compared with placebo, which is consistent with the phenomenon of early worsening of pre-existing diabetic retinopathy secondary to an initial, rapid improvement in glycaemic control.(30,37) The possible effec…”
ResultLingvay, I., Catarig, A.-M., Frias, J. P., Kumar, H., Lausvig, N. L., le Roux, C. W., Thielke, D., Viljoen, A., & McCrimmon, R. J. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30311-0 · Cited by 298 · see citing works
Ji, L., Hu, D., Pan, C., Weng, J., Huo, Y., Ma, C., Mu, Y., Hao, C., Ji, Q., Ran, X., et al. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.02.035 · Cited by 252 · see citing works
Self-citationHou, X., Lu, J., Weng, J., Ji, L., Shan, Z., Liu, J., Tian, H., Ji, Q., Zhu, D., Ge, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057319 · Cited by 174 · cited 1× · see citing works
“3%.(12) It is known that a weight loss of 5% or more is associated with improved glycaemic control in patients with T2D, and weight loss is therefore a cornerstone of T2D treatment.”
BackgroundSelf-citationKaku, K., Yamada, Y., Watada, H., Abiko, A., Nishida, T., Zacho, J., & Kiyosue, A. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13218 · Cited by 132 · cited 1× · see citing works
“A similar pattern of smaller absolute weight loss was also seen in the two trials with Japanese patients.(28,29) A significantly higher proportion of patients reached the target of HbA1c of less than 7.”
ResultPatient perspectives on once‐weekly medications for diabetes
Polonsky, W. H., Fisher, L., Hessler, D., Bruhn, D. F., & Best, J. H. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01327.x · Cited by 131 · cited 1× · see citing works
“Once-weekly GLP-1 RAs may improve patient adherence and health-related quality-of-life compared with daily formulations.(39) Furthermore, selected GLP-1 RAs (including semaglutide) offer addi-”
BackgroundSeino, Y., Terauchi, Y., Osonoi, T., Yabe, D., Abe, N., Nishida, T., Zacho, J., & Kaneko, S. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13082 · Cited by 127 · cited 1× · see citing works
“A similar pattern of smaller absolute weight loss was also seen in the two trials with Japanese patients.(28,29) A significantly higher proportion of patients reached the target of HbA1c of less than 7.”
ResultLEADER 3—Lipase and Amylase Activity in Subjects With Type 2 Diabetes
Steinberg, W. M., Nauck, M. A., Zinman, B., Daniels, G. H., Bergenstal, R. M., Mann, J. F. E., Ravn, L. S., Moses, A. C., Stockner, M., Baeres, F. M. M., et al. (2014) · Pancreas · doi:10.1097/mpa.0000000000000229 · Cited by 80 · cited 1× · see citing works
“levels during treatment with GLP-1 RAs are not indicative of pancreatitis.(38) Consistent safety findings were also seen in the Chinese population.”
Incretin physiology and pathophysiology from an A sian perspective
Cho, Y. M. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12305 · Cited by 75 · see citing works
Desouza, C. V., Cariou, B., Garg, S. K., Lausvig, N. L., Navarria, A., & Fonseca, V. A. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz072 · Cited by 57 · cited 1× · see citing works
“Absolute weight loss was smaller in the Asian subpopulation treated with semaglutide compared with other race groups in a pooled analysis across the SUSTAIN 1–5 and 7 trials.(34) Similarly, the absolute”
The journey to understanding incretin systems: Theory, practice and more theory
Yabe, D., Kuwata, H., & Seino, Y. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13123 · Cited by 7 · see citing works
Flagged first, then by citations
1 of the 39 references couldn’t be matched to a known paper.
Research works printed but not linked: 5
- International Diabetes Federation, 2019, IDF Diabetes Atlas
- 10.1016/S0140-6736(98)07037-8 · DOI · Paper page
- Rodbard H, 2016, Efficacy and safety of semaglutide once‐weekly vs placebo as add‐on to basal insulin alone or in combination with metformin in subjects with type 2 diabetes (SUSTAIN 5) [abstract], Diabetologia., 59, 364
- International Conference on Harmonisation, 1996, ICH Harmonised Tripartite Guideline for Good Cinical Practice
- Novo Nordisk A/S, 2020, Ozempic® (semaglutide), US prescribing information (PI)
Cited by
Sorted by citations
Smits, M. M., & Van Raalte, D. H. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645563 · Cited by 332 · see citing works
Clinical management and treatment of obesity in China
Zeng, Q., Li, N., Pan, X.-F., Chen, L., & Pan, A. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00047-4 · Cited by 269 · see citing works
Mahapatra, M. K., Karuppasamy, M., & Sahoo, B. M. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09699-1 · Cited by 166 · see citing works
“Two deaths (unrelated to the treatment) were reported in semaglutide group [61].”
BackgroundGlucagon‐like peptide agonists: A prospective review
Mariam, Z., & Niazi, S. K. (2023) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.462 · Cited by 114 · see citing works
Karagiannis, T., Malandris, K., Avgerinos, I., Stamati, A., Kakotrichi, P., Liakos, A., Vasilakou, D., Kakaletsis, N., Tsapas, A., & Bekiari, E. (2024) · Diabetologia · doi:10.1007/s00125-024-06144-1 · Cited by 102 · see citing works
Targeting the incretin system in obesity and type 2 diabetes mellitus
Ansari, S., Khoo, B. C. E., & Tan, T. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00979-9 · Cited by 105 · see citing works
Prasad, F., De, R., Korann, V., Chintoh, A. F., Remington, G., Ebdrup, B. H., Siskind, D., Knop, F. K., Vilsbøll, T., Fink-Jensen, A., et al. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231165169 · Cited by 88 · see citing works
Zhang, B., Cheng, Z., Chen, J., Zhang, X., Liu, D., Jiang, H., Ma, G., Wang, X., Gan, S., Sun, J., et al. (2024) · Diabetes Care · doi:10.2337/dc23-1287 · Cited by 91 · see citing works
Self-citationSemaglutide and cancer: A systematic review and meta-analysis
Nagendra, L., BG, H., Sharma, M., & Dutta, D. (2023) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102834 · Cited by 86 · see citing works
Gao, X., Hua, X., Wang, X., Xu, W., Zhang, Y., Shi, C., & Gu, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.935823 · Cited by 81 · see citing works
Yang, Y., He, L., Han, S., Yang, N., Liu, Y., Wang, X., Li, Y., Ping, F., Xu, L., Li, W., et al. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70063 · Cited by 87 · see citing works
“There were some concerns about the overall risk of bias [4, 14–18, 20, 22, 29–32] although other biases were low in all studies.”
InfluentialSelf-citationResearch progress on the PEGylation of therapeutic proteins and peptides (TPPs)
Li, C., Li, T., Tian, X., An, W., Wang, Z., Han, B., Tao, H., Wang, J., & Wang, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1353626 · Cited by 71 · see citing works
Qin, W., Yang, J., Deng, C., Ruan, Q., & Duan, K. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15386 · Cited by 72 · see citing works
Wang, F., Mao, Y., Wang, H., Liu, Y., & Huang, P. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01110-w · Cited by 71 · see citing works
Feier, C., Vonica, R., Faur, A., Streinu, D., & Muntean, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084346 · Cited by 60 · see citing works
“…severe complications revealed that a total of 9228 patients took semaglutide across 29 studies [ 23– 50 In a detailed examination of studies involving patients treated with sitagliptin [23,28,48] and liraglutide [27,43,46] as comparison groups for semaglutide, distinct outcomes have been observed.”
BackgroundResultChao, A. M., Tronieri, J. S., Amaro, A., & Wadden, T. A. (2022) · Drug Design, Development and Therapy · doi:10.2147/dddt.s365416 · Cited by 58 · see citing works
The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer
Ibrahim, S. S., Ibrahim, R. S., Arabi, B., Brockmueller, A., Shakibaei, M., & Büsselberg, D. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10192-9 · Cited by 56 · see citing works
Jiang, H., Pang, S., Zhang, Y., Yu, T., Liu, M., Deng, H., Li, L., Feng, L., Song, B., Han‐Zhang, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31328-x · Cited by 52 · see citing works
Self-citationQuarenghi, M., Capelli, S., Galligani, G., Giana, A., Preatoni, G., & Quarenghi, R. T. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14113791 · Cited by 58 · see citing works
Ocular Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis
Natividade, G. R., Spiazzi, B. F., Baumgarten, M. W., Bassotto, C., Pereira, A. A., Fraga, B. L., Scalco, B. G., Mattes, N. R., Lavinsky, D., Kramer, C. K., et al. (2025) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2025.2489 · Cited by 41 · see citing works
Cesaro, A., Pastori, D., Acerbo, V., Biccirè, F. G., Golino, M., Panico, D., Prati, F., Abbate, A., Lip, G. Y. H., & Calabrò, P. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf257 · Cited by 44 · see citing works
Yin, D., Ding, L., Zhou, H., Qiu, M., & Duan, X.-Y. (2021) · Endocrine Journal · doi:10.1507/endocrj.ej21-0129 · Cited by 42 · see citing works
Wang, W., Bain, S. C., Bian, F., Chen, R., Gabery, S., Huang, S., Jensen, T. B., Luo, B., Yuan, G., Ning, G., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06142-3 · Cited by 37 · see citing works
Self-citationKokkorakis, M., Katsarou, A., Katsiki, N., & Mantzoros, C. S. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155689 · Cited by 35 · see citing works
Khaity, A. M., Al-dardery, N. M., Albakri, K. A., Abdelwahab, O. A., Hefnawy, M. T., Yousef, Y. S. A. H., Taha, R. E. W., Swed, S., Hafez, W., Hurlemann, R., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1153648 · Cited by 35 · see citing works
“Currently, GLP-1RA is administered via subcutaneous injection (51).”
BackgroundMethodDing, Y., Shi, Y., Guan, R., Yan, S., Liu, H., Wang, Z., Li, J., Wang, T., Cai, W., & Ma, G. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2023.107031 · Cited by 31 · see citing works
Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma?
Mouhammad, Z. A., Vohra, R., Horwitz, A., Thein, A., Andreasen, J. R., Cvenkel, B., Williams, P. A., Azuara‐Blanco, A., & Kolko, M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.824054 · Cited by 30 · see citing works
“The safety and efficacy of semaglutide have been assessed in several phase II and III clinical trials (Marso et al., 2016a; Nauck et al., 2016; Ahrén et al., 2017; Aroda et al., 2017, 2019; Davies et al., 2017; Sorli et al., 2017; Ahmann et al., 2018; Kaku et al., 2018; Pratley et al., 2018, 2019; Rodbard et al., 2018…”
BackgroundHu, S., Su, X., & Fan, G. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01195-7 · Cited by 28 · see citing works
“In total, 8 trials [12, 13, 15, 22, 26, 27, 30, 32] were designed as double-blind type, while 9 trials [14, 16, 21, 23–25, 28, 29, 31] were open-label type.”
BackgroundMethodResultInfluentialSemaglutide for the prevention of atrial fibrillation: A systematic review and meta-analysis
Zhang, H., Ding, L., Liu, K., Mi, L., Zhang, A.-K., Yu, F., Yan, X.-X., Peng, F.-H., Shen, Y.-J., & Tang, M. (2024) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2024.103067 · Cited by 32 · see citing works
Małyszczak, A., Przeździecka-Dołyk, J., Szydełko-Paśko, U., & Misiuk‐Hojło, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061797 · Cited by 29 · see citing works
“…change at the end of the study; Table S2: Risk of bias assessment; Table S3: Certainty assessment; Figure S2: Pairwise meta-analysis, GLP-1RA vs. DPP-4i [21,28,29,47,64,72]; Figure S3: Pairwise meta-analysis, Semaglutide vs. placebo [6,20,22,61–63, 71 , 73 , 74 ] ; Figure S4: Pairwise meta-analysis”
BackgroundNie, Y., Zhang, Y., Liu, B., & Meng, H. (2025) · Obesity Surgery · doi:10.1007/s11695-025-07733-8 · Cited by 28 · see citing works
Wu, W., Tong, H.-M., Li, Y., & Cui, J. (2023) · Endocrine · doi:10.1007/s12020-023-03636-9 · Cited by 25 · see citing works
Self-citationAn Update on Strategies to Deliver Protein and Peptide Drugs to the Eye
Boddu, S. H. S., Acharya, D., Hala, V., Jani, H., Pande, S. V., Patel, C. A., Shahwan, M. J., Renukuntla, J., & Ranch, K. M. (2023) · ACS Omega · doi:10.1021/acsomega.3c02897 · Cited by 23 · see citing works
Alexander, G. C., Xiao, X., Dilek, S., Lewis, S. V., Deng, Q., Kim, M., Bolanle, D., Saldanha, I. J., & Mehta, H. B. (2026) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.8222 · Cited by 26 · see citing works
Zhong, P., Zeng, H., Huang, M., He, G., & Chen, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.695182 · Cited by 21 · see citing works
Kurtzhals, P., Kreiner, F. F., & Bindra, R. S. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110881 · Cited by 19 · see citing works
Tuersun, A., Hou, G., & Cheng, G. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2024.06.015 · Cited by 15 · see citing works
Ruan, Z., Ung, C. O. L., Shen, Y., Zhang, Y., Wang, W., Luo, J., Zou, H., Xue, Y., Wang, Y., Hu, H., et al. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01301-4 · Cited by 14 · see citing works
Ahmad, N., Alruwayyes, A., AlArjani, A., Tawhari, A. M., Aldosri, A., Alahmari, A., & Balaha, M. F. H. (2026) · Medicine · doi:10.1097/md.0000000000047994 · Cited by 15 · see citing works
“[37] Lingvay et al found that 62% of those who used tirzepatide and 51% of those who used semaglu-tide lost weight.”
InfluentialChen, H., Li, X., Chen, J.-Q., Ren, T., Zhang, Y., Wang, Y.-N., & Zhao, Q. (2023) · Medicine · doi:10.1097/md.0000000000034122 · Cited by 13 · see citing works
Novel Antidiabetic Drugs and Risk of Venous Thromboembolism: A Literature Review
Chen, Q., Anijs, R. J. S., Verlaan, J. P. L., Scheres, L. J. J., Klok, F. A., & Cannegieter, S. C. (2025) · Seminars in Thrombosis and Hemostasis · doi:10.1055/a-2546-0353 · Cited by 13 · see citing works
Glucagon‐like peptide‐1 receptor agonist prescribing patterns in adolescents with type 2 diabetes
Bensignor, M. O., Wolf, J. M., Rudser, K. D., Kelly, A. S., & Arslanian, S. A. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14681 · Cited by 13 · see citing works
Liu, L., Ruan, Z., Ung, C. O. L., Zhang, Y., Shen, Y., Han, S., Jia, R., Qiao, J., Hu, H., & Guo, L. (2023) · Diabetes Therapy · doi:10.1007/s13300-022-01336-7 · Cited by 12 · see citing works
Xu, J., Zhang, Y., Li, Y., Zhao, X., Zhou, W., Loghin, C., Tham, L. S., Cui, X., Cui, Y., & Wang, W. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01921-5 · Cited by 13 · see citing works
Self-citationPatel, T., Nageeta, F., Sohail, R., Butt, T. S., Ganesan, S., Madhurita, F., Ahmed, M. W., Zafar, M., Zafar, W., Zaman, M., et al. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2239830 · Cited by 12 · see citing works
“From this process, three randomized controlled trials (Rcts) were identified [10,14,15].”
MethodHe, Y., Mi, N., Cheng, Z., Xue, H., Han, J., Wang, H., Wang, H. H., Wu, J., Shi, X., Zhao, S., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00196-2 · Cited by 14 · see citing works
Self-citationMazdutide versus dulaglutide in Chinese adults with type 2 diabetes
Guo, L., Zhang, B., Xue, X., Zhang, B., Cai, H., Jiang, H., Zhang, L., Jin, P., Wang, X., Cheng, Z., et al. (2025) · Nature · doi:10.1038/s41586-025-10031-z · Cited by 12 · see citing works
Osumili, B., Sapin, H., Yang, Z., Ranta, K., Paik, J. S., & Blüher, M. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01728-5 · Cited by 12 · see citing works
WANG, Q., Cui, Q., Xu, Y., Prud’homme, G. J., Yang, Y., Zhu, D., Li, Y., Yang, Y., & Li, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16452 · Cited by 11 · see citing works
Self-citationBabazadeh, D., Wyatt, S., & Steinberg, F. M. (2025) · Advances in Nutrition · doi:10.1016/j.advnut.2025.100491 · Cited by 13 · see citing works
Rong, J., Leng, X., Jiang, K. P., Tan, J., & Dong, M. (2025) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-025-01454-4 · Cited by 18 · see citing works
“Furthermore, lifestyle interventions combined with testosterone therapy are particularly effective in preventing and reversing T2D, especially in obese patients with low testosterone levels [147, 360–362].”
Janani, L., Bamehr, H., Tanha, K., Mirzabeigi, P., Montazeri, H., & Tarighi, P. (2021) · Drug Research · doi:10.1055/a-1555-2797 · Cited by 11 · see citing works
Luo, Y., Jiang, H., Shi, B., Cai, H., Wang, H., Li, S., Qiu, W., Li, Y., Zhou, R., Deng, H., et al. (2025) · Contemporary Clinical Trials · doi:10.1016/j.cct.2025.108150 · Cited by 10 · see citing works
Self-citationHuang, X., Wu, M., Lin, J., Mou, L., Zhang, Y., & Jiang, J. (2024) · Medicine · doi:10.1097/md.0000000000038236 · Cited by 10 · see citing works
Shabutdinova, O. R., Dautov, A. R., Samkov, A. A., Kononenko, A. V., Sargaliev, A. F., Davletshin, A. R., Andresova, P. A., Zarbeeva, K. R., Torshkhoeva, D. A., Rakhmonkulov, U. A., et al. (2023) · Problems of Endocrinology · doi:10.14341/probl13197 · Cited by 10 · see citing works
Lee, B., Cho, Y. M., Kim, S. G., Ko, S., Lim, S. K., Dahaoui, A., Jeong, J. S., Lim, H. J., & Yu, J. M. (2024) · Diabetes Therapy · doi:10.1007/s13300-023-01515-0 · Cited by 9 · see citing works
Self-citationThe expanding role of semaglutide: beyond glycemic control
Zarei, M., Sabetkasaei, M., Mozafari, M., & Zaeri, S. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01663-z · Cited by 9 · see citing works
Ruan, Z., Jiang, Y., Shi, H., Jia, R., Ung, C. O. L., & Hu, H. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2174099 · Cited by 9 · see citing works
Dorneles, G. P., Algeri, E. D. B. D. O., Lauterbach, G., Pereira, M. G., & Fernandes, B. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2303-8558 · Cited by 8 · see citing works
“Furthermore, clinical trials demonstrated that semaglutide lowers the thickness of epicardial fat and significantly reduces the likeli - hood of major adverse cardiovascular events and stroke compared to placebo [42, 43].”
BackgroundBerković, M. C., Režić, T., Bilić-Čurčić, I., & Mrzljak, A. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i20.6759 · Cited by 8 · see citing works
Wu, R., Xing, B., Huang, Y., Zhou, Z., Sun, B., Yu, L., & Wang, H. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1554795 · Cited by 9 · see citing works
Ji, L., Ahmann, A., Åhrén, B., Capehorn, M., Hu, P., Lingvay, I., Liu, W., Rodbard, H. W., Shen, Z., & SORLI, C. H. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15309 · Cited by 7 · see citing works
Self-citationPetrova, L., Andreevska, K., Parvova, I., & Petkova, V. B. (2024) · Pharmacia · doi:10.3897/pharmacia.71.e132148 · Cited by 7 · see citing works
Yang, L., Duan, X.-Y., Hua, P., Wu, S., & Liu, X.-B. (2024) · Journal of Research in Medical Sciences · doi:10.4103/jrms.jrms_693_23 · Cited by 6 · see citing works
Gojani, E. G., Wang, B., Li, D., Kovalchuk, O., & Kovalchuk, I. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26010421 · Cited by 6 · see citing works
Gu, S., Gu, J., Wang, X., Wang, X., Li, L., Gu, H., & Xu, B. (2024) · Health Economics Review · doi:10.1186/s13561-024-00499-2 · Cited by 5 · see citing works
“Both in the scenario analyses of using alternative patient profiles and treatment effects [6] and in the PSA, once-weekly semaglutide 0.5 mg arm and 1 mg arm BMI body mass index, HbA1c hemoglobin Alc, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year † For the costs, data…”
BackgroundMethodInfluentialSemaglutide-Associated Gastric Pneumatosis
Turunen, A. M., Coombs, R. A., & Garg, S. K. (2024) · ACG Case Reports Journal · doi:10.14309/crj.0000000000001579 · Cited by 5 · see citing works
Abusedera, O., Sherif, J., Smida, M., & Fredericks, S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14248734 · Cited by 5 · see citing works
Alwafi, H. H., Alharbi, S. S., Al-adwani, G. A., Alsanosi, S., Oyelade, T., Almalki, F., Thalib, H. I., Naser, A. Y., Alfahmi, M. Z., Alotaibi, B. J., et al. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1639704 · Cited by 4 · see citing works
Reconsidering Semaglutide Use for Chronic Obesity in Patients of Asian Descent: A Critical Review
Lu, J., Williams, G., & Fanning, S. (2024) · Cureus · doi:10.7759/cureus.73111 · Cited by 3 · see citing works
Ji, L., Lu, Y., Shen, Z., Hu, P., Liu, W., Zhang, Q., & Shi, B. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15888 · Cited by 3 · see citing works
“19 Eligible participants had T2D (HbA1c 7.0% – 10.5% [53 – 91 mmol/mol]), were ≥ 18 years old, and had been treated with metformin monotherapy at a stable dose of ≥ 1500 mg (or a maximum tolerated dose of ≥ 1000 mg) for 60 days before screening.”
InfluentialSelf-citationKo, D., Kim, D. H., Tan, F. X. N., Ho, G. J. K., Chandra, R., Xuan, Z. Z., Tham, E. K. J., Tang, N. S. Y., Yang, H. S., Koh, J. W. H., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102614 · Cited by 2 · see citing works
Regulatory cycles of orexin and glucagon-Like peptide-1 in postviral syndromes
Ruhrländer, J., Schieffer, E., & Schieffer, B. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag009 · Cited by 2 · see citing works
Liu, M. N., Wang, X., Li, M., Yang, E., Yang, A., Yuan, M., Dong, R., Qin, G., Liu, P., Li, C., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102874 · Cited by 2 · see citing works
“13 Accordingly, Part A of the trial employed a dose-escalation regimen from 0.5 mg to 4.0 mg, mirroring the dose-escalation strategy used for semaglutide, 4,15 but with a slightly higher target dose.”
InfluentialSelf-citationKhamnueva, L. Y., & Андреева, Л. С. (2023) · Problems of Endocrinology · doi:10.14341/probl13245 · Cited by 2 · see citing works
Preoperative Assessment of a Patient Undergoing Bariatric Surgery
Yuan, J. J., Bangalore, R., Darwish, D., Moon, T. S., & Wadhwa, A. N. (2023) · Anesthesiology Clinics · doi:10.1016/j.anclin.2023.07.005 · Cited by 2 · see citing works
GLP-1RA may have varying effects on cardiac structure in patients with ASCVD depending on BMI
Xu, L., & Zhu, D. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1355540 · Cited by 2 · see citing works
Hu, Y. C., Chen, X., Zou, H., Zhang, H., Ni, Q., Li, Y., Ung, C. O. L., Hu, H., & Mu, Y. (2024) · Advances in Therapy · doi:10.1007/s12325-024-03082-7 · Cited by 2 · see citing works
Self-citationBai, S., Lin, C., Jiao, R., Cai, X., Hu, S., Lv, F., Yang, W., Zhu, X., & Ji, L. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.01.008 · Cited by 1 · see citing works
Self-citationShi, C., Tan, Y., Hu, S., Qin, Y., Tang, Y., Wang, Y., & Fan, G. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15552 · Cited by 1 · see citing works
“4,5 However, because current evidence on semaglutide in a broad range of individuals with T2DM mainly derives from randomized controlled trials (RCTs), it is important to collect data on its use in real-world studies assessing semaglutide against comparators, to complement and validate the results…”
BackgroundJi, L., Huang, D., Lin, X., Dong, X., Lü, L., Sun, Q., Sun, X., Mao, L., Zhao, S., Wang, Q., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70036 · Cited by 1 · see citing works
Self-citationJia, W., Jiang, F., Xu, Y., Li, Y., Bao, Y., & WANG, Q. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70112 · Cited by 1 · see citing works
“39 A meta-analysis further supports similar HbA1c reductions in Asian and non-Asian patients.”
Self-citationChen, Q., Chen, T., Lin, W., & Chen, X. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s585436 · Cited by 1 · see citing works
Wang, S., Hu, P., Shen, Z., & Chen, L. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01848-6 · Cited by 1 · see citing works
“However, although As expected, greater HbA 1c reductions of 1.4%-points and 1.7%-points were observed in the SUSTAIN China trial of once-weekly sema-glutide 0.5 mg and 1.0 mg, respectively, over 30 weeks [20].”
InfluentialControversial effects of metformin on human physiology and pathophysiology
Fang, S., Liu, Q., Lu, Y., & Zhang, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1799374 · Cited by 1 · see citing works
Liu, M. R., Cheng, Z. F., Li, L., Cai, H., Liu, J., Liu, J., Zheng, Y., Wang, S., Zhao, J., Yang, W., et al. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-04623 · Cited by 1 · see citing works
Self-citationXiao-yu, Z., Deng, C.-H., Zhong, J.-Y., Wu, Q., Chen, Q.-X., Gao, X.-Y., Xu, Y., Jiang, Z., Guo, M., & Teng, F. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104859 · Cited by 1 · see citing works
Zhang, K., Zhao, A., Wang, Z., Ye, K., Xu, Z., Gong, X., & Zhu, G. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01449-1 · Cited by 1 · see citing works
“The results have consistently shown that semaglutide has superior efficacy and a better safety profile than previous antihyperglycemic drugs [10–14].”
Siva, B., Sherin, S., Somabattini, R. A., & Nanjappan, S. K. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116960 · Cited by 1 · see citing works
Weber, P., Meluzínová, H., & Weberová, D. (2022) · Klinická farmakologie a farmacie · doi:10.36290/far.2021.027
Bando, H., Hisako, Y., Kato, Y., OGURA, K., Kato, Y., & Setsuko, K. (2022) · Journal of Obesity and Diabetes · doi:10.33805/2638-812x.126
GLP-1 RECEPTORIŲ AGONISTŲ REIKŠMĖ 2 TIPO CUKRINIU DIABETU SERGANČIŲ PACIENČIŲ SVORIO MAŽINIMUI
Viliušytė, M., Maleckas, A., & Malinauskas, M. (2024) · Health Sciences · doi:10.35988/sm-hs.2024.021
“Vartojant 0,5 mg semaglutido, svorio pokytis buvo atitinkamai -4,6 kg ir -2,9 kg, o vartojant 1 mg semaglutido, pokytis atitinkamai -6,5 kg ir -4,2 kg. Pastebėta, kad tame tyrime, kuriame svorio pokytis buvo šiek tiek mažesnis [41], vartojant tokią pat dozę, tyrimo laikas taip pat buvo trumpesnis.”
BackgroundGhosh, S. K., WANGNOO, S. K., Chittawar, S., Damodharan, S., Kadam, Y., Kalra, P., Kumar, K. P. S., Periyandavar, I., Sharma, S. K., & Zargar, A. H. (2024) · Journal of Endocrinology and Metabolism · doi:10.14740/jem946
Garzaie, A. A. A., Taib, H., Dalbhi, S. A., Khan, M. S., & Kofi, M. A. (2024) · European Journal of Medical and Health Research · doi:10.59324/ejmhr.2024.2(5).07
Chilunga, F. P., & Mkoma, G. F. (2024) · Diabetologia · doi:10.1007/s00125-024-06297-z
“While studies in populations of non-European descent are emerging and commendable, such as the SUSTAIN China trial, they remain scarce [2].”
The Physiology of Semaglutide in Relation to Glucagon Like Peptide-1: A Comprehensive Review
Barakat, G. M., Hassan, S. E. H., Issa, H., & Ramadan, W. (2025) · Current Drug Therapy · doi:10.2174/0115748855404783250917112146
Xu, Y., Ji, G., Shi, C., Tan, Y., Wang, L., & Gui, Y. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112954
Gu, S., Gu, J., Wang, X., Wang, X., Li, L., Gu, H., & Xu, B. (2024) · Figshare · doi:10.6084/m9.figshare.25530430
Gu, S., Gu, J., Wang, X., Wang, X., Li, L., Gu, H., & Xu, B. (2024) · Figshare · doi:10.6084/m9.figshare.25530189
Semaglutide: Scoping Review with ☸SAIMSARA
SAIMSARA (2026) · SAIMSARA Journal · doi:10.62487/saimsara45190890
- Authors
- Ji, L., Dong, X., Li, Y., Li, Y., Lim, S., Liu, M., Ning, Z., Rasmussen, S., Skjøth, T. V., Yuan, G., & Eliaschewitz, F. G.
- Affiliations
- Peking University People's Hospital (CN)
- Jinan Central Hospital (CN)
- Fudan University (CN)
- Seoul National University (KR)
- Tianjin Medical University (CN)
- Novo Nordisk (China) Pharmaceuticals Co., Ltd Beijing China
- Novo Nordisk (Denmark) (DK)
- Affiliated Hospital of Jiangsu University (CN)
- CPClin/DASA Centro de Pesquisas Clínicas São Paulo Brazil
- Corresponding author
- Ji, Linong
- ORCID
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2021-01-03
- Volume
- 23
- Issue
- 2
- Pages
- 404-414
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- PMC
- PMC7839591
- OpenAlex
- W3093123473
- Cited by
- 113
- References
- 39
- Citations by year
- 2026: 23 · 2025: 23 · 2024: 28 · 2023: 20 · 2022: 11 · 2021: 7 · 2020: 1
- FWCI
- 7.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Obesity and Metabolism (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Keywords
- semaglutide, sitagliptin, type 2 diabetes, GLP-1 receptor agonists, metformin add-on therapy, glycemic control, HbA1c, weight loss, hypoglycemia, adverse events, Chinese patients, DPP-4 inhibitors
- MeSH terms
- Sitagliptin Phosphate, Semaglutide, Adult, China, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Glucagon-Like Peptides, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Metformin, Treatment Outcome, Republic of Korea
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
